Baird Downgrades Theravance Biopharma (TBPH) to Underperform

October 12, 2016 6:02 AM EDT
Get Alerts TBPH Hot Sheet
Price: $30.84 +1.58%

Rating Summary:
    4 Buy, 0 Hold, 2 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade TBPH Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Baird downgraded Theravance Biopharma (NASDAQ: TBPH) from Neutral to Underperform with a price target of $24.00 (from $19.00), saying valuation is ahead of itself.

Analyst Brian Skorney commented, "Theravance has done a great job building enthusiasm for its Jak inhibitor programs, which could be differentiated in the hot IBD space, while also making the case for the multiple shots on goal that characterize the company's remaining pipeline. But a long path to approval and significant spend along the way makes the current valuation appear unsustainable and we think the stock is likely to see a correction. As a result, we are downgrading to Underperform and setting a target price of $24."

For an analyst ratings summary and ratings history on Theravance Biopharma click here. For more ratings news on Theravance Biopharma click here.

Shares of Theravance Biopharma closed at $37.44 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst PT Change, Downgrades, Hot Downgrades

Related Entities

Robert W Baird

Add Your Comment